POSIFLEX-TECHNOLOGY
25.6.2024 08:53:31 CEST | Business Wire | Press release
Posiflex Technology Inc., a global leader in Point of Sale (POS) systems and Online to Offline (O2O) solutions, today announced its latest mobile POS tablet offering - the Opera MT-6200 Series, which explores mobility and efficiency with sleek, lightweight yet semi-rugged designs. It supports Android 13 with GMS Certification or Windows 11 IoT OS, available in both x86 and RISC variants. With screen sizes of 8" and 10.1", the series features dockability with a USB Type-C connector, allowing for fast power charging. Complemented by a variety of POS accessories to enhance functionality, they are designed to meet the demands of the mobile economy across various industries. This includes retail stores, hospitality, logistics, inventory/warehouse management, and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624392969/en/
The Posiflex Opera MT-6200 Series Mobile POS Tablet (Photo: Business Wire)
Superior Durability for Tough Applications
Leveraging Posiflex's cutting-edge engineering excellence, the Opera MT-6200 Series achieves a harmonious balance between the conflicting demands of tablets. It combines a lightweight and thin design with high-performance computing and semi-rugged durability. Equipped with a Corning Gorilla III touch screen, a PCAP multi-touch TFT LCD with 300nits brightness. The tablet is ideal for heavy use in various environments with ease. To ensure durability, the series incorporates semi-rugged designs, including IP54 water and dust resistance. It can withstand drops from 1 meter (1.2 meters with a protective case) and features a unique anti-slip design, providing a secure grip during handheld use. These elements collectively make the Opera MT-6200 Series resilient against the challenges of daily use.
Efficient USB Type-C for Fast Charging
Fast power charging and power efficiency are also essential to support the superior mobility of POS tablets. The Opera MT-6200 Series features an IPX7 waterproof USB Type-C connector for docking and rapid power charging. This feature enhances the overall user experience, providing convenience and efficiency for on-the-go professionals in various business environments. In particular, the smart docking station has a special bracket for protection and convenient charging, but when the tablet is in a rubber protective case, it can be docked directly to the charger without removing the case.
Flexible Functions for Customizable User Experience
In addition to a built-in 2D scanner and NFC module, Opera MT-6200 Series tablets offer programmable buttons on both sides of the screen bezel for customizable functionality, allowing customization for your specific applications. Opera MT-6200 series leads the way with seamless connectivity, supporting WiFi 5/6 and Bluetooth 5.0/5.2, ensuring a superior and efficient user experience.
Wide Range of Accessories to Extend Functionality and Maximize Convenience
As one of the manufacturers in the world capable of producing a complete range of POS terminals and peripherals from a single source, Posiflex offers a wide range of optional accessories including fingerprint reader, MSR, shoulder strap, protective case with rotatable handheld strap, touch pen and more. The smart docking station is also equipped with a variety of I/O ports to extend the functions for stationary operations - all to maximize flexibility, user value and convenience.
About POSIFLEX Group
Posiflex Group is a global leading Commercial AIoT platform powered by smart Online-to-Offline (O2O) and Software-defined Embedded Appliance Solutions. Pillared by three brands, Posiflex Group consists of Posiflex as global top 5 brand in POS & Kiosk, Portwell as Embedded Foundry for AIoT Edge Compute, and KIOSK Information Systems (KIS) for managed self-service automation – together with a common mission to enable optimized productivity and superior customer journey across the connected world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240624392969/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom